Let's transform UTERINE HEALTH
together!
Every woman faces uterine disorders throughout her lifetime: excessive bleeding, chronic pain, infertility...
Yet, the only solutions they are offered are either invasive surgery or high-dose hormonal treatments that cause debilitating side effects.
At Womed, we develop intrauterine therapies to relieve women from the burden of infertility, bleeding and endometriosis while respecting the integrity of their body.
Join the movement on one of our partner platforms
You can invest in Womed through either Lita or Capital Cell
Lita est la plateforme pionnière de l'investissement durable et citoyen en Europe. En investissant en direct sur Lita, vous financez des entreprises développant des solutions innovantes dans les domaines de la santé, de l'écologie ou du social. En 10 ans d'existence, ce sont plus de 250 entreprises à impact qui ont pu être financées à un moment stratégique de leur développement.
If you are interested in investing in high-tech life science that can make an impact in patients' lives, Capital Cell is the leading European platform for early-stage biotech and life science ventures. Selected by experts, backed by visionaries, we invite you to shape the future of health with us, one investment at a time.
.png){kind=logo}
Investing in unlisted companies carries a significant risk of partial or total loss of the amounts invested, as well as a risk of illiquidity.
How do we deliver gentle and precise care?
Our foundational technology, a patented tri-block copolymer, has been developed for several years at the University of Montpellier.
Its unique properties allow for easy insertion through the cervix and tunable degradability. It can also deliver low-doses of drugs right inside the uterus where it is needed.
We are leveraging this platform into a powerful pipeline of 4 products targeting intrauterine adhesions, fibroids, acute bleeding, and endometriosis.
How will your contribution boost our development?
1
Global Commercialization of Womed Leaf
Accelerate the international rollout to make our FDA-approved, first-in-class adhesion barrier accessible to every woman recovering from uterine surgery.
2
Phase II Clinical Study of Eynia
Fund the phase II clinical study for our game-changing fibroid treatment, to bring a non-surgical, non-systemic solution to market.
3
Pipeline Acceleration for Acute Bleeding & Endometriosis
Drive the development of our next-generation therapies to tackle two of the most debilitating and underserved female health conditions.